Spots Global Cancer Trial Database for acute myeloid leukemia with flt3 activating mutations that has relapsed or been refractory after one or more prior therapies
Every month we try and update this database with for acute myeloid leukemia with flt3 activating mutations that has relapsed or been refractory after one or more prior therapies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations | NCT01657682 | Acute Myeloid L... | Crenolanib besy... | 18 Years - | Arog Pharmaceuticals, Inc. |